Asia
Proxalutamide, a selective high-affinity silent antagonist of the androgen receptor, is being developed by Chinese biotech, Kintor Pharmaceutical Limited (9939.HK).
The help wanted signs are up across the biopharma industry. Companies are opening and expanding facilities, which is good news for job seekers.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
Biopharma and life sciences from across the globe provide updates on their businesses and pipelines.
Shanghai-based Alebund Pharmaceuticals has raised $60 million in a new Series B financing round that will be harnessed to further drive the company’s focus on renal disease.
There’s a fair amount of new information coming out about COVID-19 and vaccines. Here’s a roundup of some of the top stories.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
One year after Astellas and California-based Cytokinetics extended an agreement to develop Skeletal Sarcomere Activators, the Japanese pharma company is walking away from the deal.
PRESS RELEASES